NCT02136940

Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

A Phase 2a, Multicenter, Randomized, Double-masked, Placebo-controlled, Parallel-group Study of AMA0076 in Topical Ocular Formulation for Safety, Tolerability and Efficacy in Reduction of Intraocular Pressure in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 103 (actual)
• Sponsor: Amakem, NV · Industry
• Sex: All
• Age: 30 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The objective of this parallel group study is to evaluate the safety, tolerability and efficacy of AMA0076 in reduction of intraocular pressure in subjects with primary open-angle glaucoma or ocular hypertension.

Conditions

• Glaucoma
• Ocular Hypertension
• Eye Disease

Interventions

Type	Name	Description
DRUG	AMA0076
DRUG	Placebo

Timeline

• Start date: 2014-04-01
• Primary completion: 2014-11-01
• Completion: 2014-12-01
• First posted: 2014-05-13
• Last updated: 2015-01-21

Locations

9 sites across 1 country: United States